Our lead candidate in HSV-2 is GEN-003, a first-in-class, protein subunit T cell-enabled therapeutic vaccine, or immunotherapy, designed to reduce the duration and severity of clinical symptoms associated with moderate-to-severe HSV-2, and to control transmission of the infection. Unlike previous HSV-2 vaccine candidates, GEN-003 is a protein subunit vaccine designed to mount responses from both the T and B cell arms of the immune system, which is believed to be critical to achieving long-term control of this chronic infection. GEN-003 includes the antigens ICP4 and gD2, as well as the proprietary adjuvant Matrix-M™.
Genocea recently completed a Phase 1a/2 clinical study of GEN-003. Read a Q&A about the clinical trial here and the results here, here and here. To see a presentation of initial results, see here. To see a presentation of immunogenicity data from this trial, see here.
Consistent with its development plan, Genocea is next exploring additional combinations of proteins and adjuvant in a Phase 2 dose optimization study, which may identify a dose which further improves the magnitude or durability of effect of GEN-003.
If approved, we believe GEN-003 would be the first therapeutic vaccine to address HSV-2 – or any infectious disease. Please click here for more information on our clinical trial.
Information about GEN-003 for Patients
Please click here for information for patients about GEN-003.